Headaches and Wegovy: what the side-effect evidence actually shows

You've just taken your first Wegovy injection and now you have a headache

That scenario plays out for a number of people starting semaglutide. The NHS semaglutide medicine page lists headache as a common side effect, meaning it affects somewhere between 1 in 10 and 1 in 100 people taking the medicine. It tends to surface in the early weeks, when the body is adjusting to a dose it hasn't encountered before.

The mechanism isn't a mystery. Wegovy slows gastric emptying and can reduce appetite sharply, which sometimes means people eat and drink less than usual without fully realising it. Mild dehydration and a lower calorie intake in the same week are a reliable recipe for a headache. Some people also experience nausea at the start of treatment, and if they feel sick enough to reduce their fluid intake, that compounds things. The headache, in short, often isn't the drug acting directly on your head. It's a downstream effect of the changes in appetite and digestion.

Timing matters here. Many people find the first injection falls on a Monday, or just after payday when they've finally decided to start. Either way, if you're wondering what to do when a Wegovy headache arrives that first week, drinking more water, eating little and often rather than skipping meals, and resting are worth trying before reaching for the paracetamol.

If the headache is mild and resolves within a day or two, that is broadly consistent with what clinical experience and the pattern of headaches reported on Wegovy suggest.

How headaches during Wegovy tend to behave over time

For most people, headaches that appear at the start of treatment don't last. The dose-titration schedule built into Wegovy treatment (starting low and stepping up gradually, with a prescriber's oversight) exists precisely to give the body time to adjust. As the weeks progress and appetite and fluid intake stabilise, headache frequency typically falls.

The picture can repeat, though, at each dose increase. Someone moving from 1.0 mg to 1.7 mg, or from 1.7 mg to 2.4 mg, may notice the same brief period of headache and mild nausea returning. That is normal and not a sign that the treatment is failing or harming. It is the same adjustment process at a new starting point. Headaches linked specifically to semaglutide's mechanism are explored in more detail on a companion page, if you want the pharmacology behind it.

Practical steps that consistently help: keep fluid intake steady across the day rather than catching up in the evening; eat smaller meals more regularly if a larger meal is now unappealing; and keep paracetamol to hand for the first week after each new dose. The STEP 1 trial, which underpins Wegovy's licence and was published in the New England Journal of Medicine, did not identify headache as a primary safety signal, it was a common but manageable side effect in the trial data, not a reason for most participants to stop.

If you're comparing how Wegovy's headache pattern sits against other experiences, this page looks at headaches that appear in the hours immediately after each injection, which is a slightly different question.

When a headache on Wegovy needs medical attention

Most headaches during Wegovy treatment are unremarkable. A small number are not, and it is worth being clear about the difference.

Get same-day medical help if a headache is the worst of your life, comes on suddenly like a thunderclap, or is accompanied by vision changes, facial drooping, confusion, weakness on one side of the body, or difficulty speaking. These are not typical drug side-effect patterns. They need urgent assessment regardless of what medicine you are taking.

Seek prompt advice from a clinician, rather than waiting it out, if a headache is severe and doesn't respond to standard pain relief, if it persists for more than two to three days without improving, or if it arrives alongside severe or persistent stomach pain that radiates to the back. That last combination warrants attention because acute pancreatitis is a known, though infrequent, side effect of GLP-1 medicines. The MHRA highlighted this in a Drug Safety Update in January 2026 and recommends that anyone experiencing severe, persistent abdominal pain while on a GLP-1 medicine seeks medical help promptly.

Vomiting blood is a separate and serious symptom that requires immediate assessment. There is a dedicated page covering vomiting blood as a reported Wegovy symptom for anyone concerned about that specifically.

For suspected side effects that don't require emergency care but still feel worth recording, the MHRA's Yellow Card reporting scheme is open to patients and carers directly. Reports like this help the regulator build a clearer picture of how medicines behave in the real world, beyond clinical trials.

Our prescribers at nume discuss the full side-effect profile, including headache, as part of every consultation. Check your eligibility to speak with a GPhC-registered Independent Prescriber about whether Wegovy is suitable for you.